Chimeric VEGF peptides

Details Chimeric VEGF peptides Chimeric VEGF peptides

2005-02-07

2011-12-20

Allen, Marianne P (Department: 1647)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C424S184100, C424S185100, C514S008100, C536S023400

Reexamination Certificate

active

08080253

ABSTRACT:
Compositions for and methods of treating patients with malignancies associated with overexpression of VEGF, particularly ovarian cancer are provided herein. The compositions include but are not limited to certain VEGF epitopes, multivalent peptides comprising the epitopes, and chimeric peptides comprising one or more of the epitopes and a T cell epitope.

REFERENCES:
patent: 6339139 (2002-01-01), Gu et al.
patent: 7060284 (2006-06-01), Kaumaya et al.
patent: 2006/0110400 (2006-05-01), Glover et al.
patent: WO 94/00153 (1994-01-01), None
patent: WO 95/17210 (1995-06-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 96/33739 (1996-10-01), None
patent: 0034337 (2000-06-01), None
patent: 2005/076972 (2005-08-01), None
Boocock et al. “Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma”,J Natl Cancer Inst(1995) vol. 87, pp. 506-516.
Chou et al.,, “Prediction of the secondary structure of proteins from their amino acid sequence”,Adv. Enzymol. Relat. Subj. Biochem. (1978) vol. 47, pp. 45-148.
Cole et al., “The EBV-Hybridoma Technique and its Application to Human Lung Cancer” inMonoclonal Antibodies and Cancer Therapy(Alan R. Liss, Inc., 1985) pp. 77-96.
Dakappagari et al., “Prevention of Mammary Tumors with a Chimeric HER-2 B-cell Epitope Peptide Vaccine”,Cancer Research(2000) vol. 60, pp. 3782-3789.
Deulofeut et al., “Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated individuals”,Mol Immunol(1993) vol. 30, pp. 941-948.
Gentz et al., “Bioassay for trans-activation using purified human immunodeficiency virustat-encoded protein: Trans-activation requires mRNA synthesis”,Proc. Natl. Acad. Sci. USA(1989) vol. 86, pp. 821-824.
Gordon et al., “Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer”,J Clin Oncol(2001) vol. 19, pp. 843-850.
Hanahan et al., “Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis”.Cell1996;86:353-64.
Hollingsworth et al., “Tumor angiogenesis in advanced stage ovarian carcinoma”,Am J Pathol(1995) vol. 147, pp. 33-41.
Hopp et al., “Prediction of protein antigenic determinants from amino acid sequences”,Proc. Natl. Acad. Sci. USA(1981) vol. 78, No. 6, pp. 3824-3828.
Jemal et al., “Cancer Statistics, 2003”,CA Cancer J Clin(2003) vol. 53, pp. 5-26.
Karplus et al., “Prediction of Chain Flexibility in Proteins, A Tool for the Selection of Peptide Antigens”,Naturwiss(1985) vol. 72, pp. 212-213.
Kaumaya et al., “De novo engineering of protein immunogenic and antigenic determinants”, inPeptides(Basava and Anantharamaiah, Ed., Birkauser, Boston, 1994) vol. 9, pp. 133-164.
Kaumaya et al., “Peptide vaccines incorporating a “promiscuous” T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity”,J Mol Recognit(1993) vol. 6, pp. 81-94.
Kaumaya et al., “Synthesis and biophysical characterization of engineered topographic immunogenic determinants with αα topology”,Biochemistry(1990) vol. 29, pp. 13-23.
Kim et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo”,Nature(1993) vol. 362, pp. 841-844.
Kobs-Conrad et al., “Engineered Topographic Determinants with αβ, βαβ, and βαβα Topologies Show High Affinity Binding to Native Protein Antigen (Lactate Dehydrogenase-C4)”,The Journal of Biological Chemistry(1993) vol. 268, No. 34, pp. 25285-25295.
Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity”,Nature(1975) vol. 256, pp. 495-497.
Kozbor et al., “The production of monoclonal antibodies from human lymphocytes”,Immunology Today(1983) vol. 4, pp. 72-79.
LeCouter et al., “Identification of an angiogenic mitogen selective for endocrine gland endothelium”,Nature(2001) vol. 412, pp. 877-884.
Leung et al., “Vascular endothelial growth factor is a secreted angiogenic mitogen”,Science(1989), vol. 246, pp. 1306-1309.
Margolin et al., “Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data”,J Clin Oncol(2001) vol. 19, pp. 851-856.
Markman et al., “Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.”,J Clin Oncol(2003) vol. 21, pp. 2460-2465.
McGuire et al., “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer”,N Engl J Med(1996)vol. 334, pp. 1-6.
Nair et al., “Synergy between tumor immunotherapy and antiangiogenic therapy”,Blood(2003) vol. 102, No. 3, pp. 964-971.
Olson et al., “Vascular permeability factor gene expression in normal and neoplastic human ovaries”,Cancer Res(1994) vol. 54, p. 276-80.
Paley et al., “Vascular endothelial growth factor expression in early stage ovarian cancer”,Cancer(1997) vol. 80, pp. 98-106.
Passaniti et al., “A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor”,Lab Invest(1992) vol. 67, No. 519-28.
Peoples et al., “Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2
eu-derived peptide”,Proc. Natl. Acad. Sci. USA(1995) vol. 92, pp. 432-436.
Rose et al., “Hydrophobicity of Amino Acid Residues in Globular Proteins”,Science(1985) vol. 229, pp. 834-838.
Sakaguchi, “Regulatory T cells: key controllers of immunologic self-tolerance”,Cell(2000) vol. 101, pp. 455-458.
Tempfer et al., “Vascular endothelial growth factor serum concentrations in ovarian cancer”,Obstet Gynecol(1998) vol. 92, pp. 360-363.
Thornton et al., “Location of ‘continuous’ antigenic determinants in the protruding regions of proteins”,EMBO J. (1986) vol. 5, pp. 409-413.
Wagner et al., “Immunological Consolidation of Ovarian Carcinoma Recurrences with Monoclonal Anti-Idiotype Antibody ACA125: Immune Responses and Sruvival in Palliative Treatment”,Clinical Cancer Research(2001) vol. 7, pp. 1154-1162.
Wei et al., “Immunogene therapy of tumors with vaccine based onXenopushomologous vascular endothelial growth factor as a model antigen”,PNAS(2001) vol. 98, No. 20, pp. 11545-11550.
Welling et al., “Prediction of sequential antigenic regions in proteins”,FEBS Lett. (1985) vol. 188, pp. 215-218.
Wolff et al., “Direct gene transfer into mouse muscle in vivo”,Science(1990) vol. 247, pp. 1465-1468.
Lu, et al., “Identification of the residues in the extracellular region of KDR important for the interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies,” Journal of Biological Chemistry, (2000), vol. 275, No. 19, pp. 14321-14330.
Yang, et al., “Design and Synthesizing of human vascular endothelial growth factor (VEGF) peptide,”(1999), U.S. National Library of Medicine; Bethesda, MD, US, (English abstract only).

Affiliated with

Also associated with

Rating

Chimeric VEGF peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric VEGF peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric VEGF peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4267131